Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs TransMedics Group Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.03 (market cap $378.77M), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 7.2× JPMorgan Diversified Return International Eqty ETF's market cap, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and TransMedics Group Inc for 24 Days on average.
| JPIN | TMDX | |
|---|---|---|
Market Cap | $378.77M | $2.74B |
Volume | 13,861 | 949,331 |
52-Week High | $77.80 | $150.42 |
52-Week Low | $64.96 | $61.99 |
Typical Hold Time | 120 Days | 24 Days |
Sector | — | Health |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $72.875, down 0.09% with bearish technical signals dominating. The ETF shows oversold conditions with RSI readings below 25, while moving averages and oscillators indicate strong selling pressure. Recent analysis highlights JPIN's focus on international value stocks through a smart beta approach.
The ETF faces significant technical headwinds despite oversold conditions. Investors should weigh the bearish momentum against potential value opportunities in international markets, with the upcoming dividend payment in September 2026 providing income consideration.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
